MedPath

Comparison of Acceleromyography (AMG) and Mechanomyography (MMG) for Establishing Potency of Neuromuscular Blocking Agents

Phase 4
Completed
Conditions
Neuromuscular Blockade
Interventions
Device: TOF-Watch SX (Acceleromyography)
Registration Number
NCT00660413
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

The purpose of this study was to compare two methods for neuromuscular monitoring, acceleromyography and mechanomyography for establishing the dose-response relationship and the potency of a neuromuscular blocking agent using rocuronium as an example. We hypothesized that there would be no significant difference between potencies estimated using acceleromyography and mechanomyography.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • ASA I-III
  • Ideal weight +/-20%
  • Both arms available for neuromuscular monitoring
  • Surgery in supine position
  • Participated surgery time more than 30 min
Exclusion Criteria
  • Pregnant and breast-feeding women
  • Patients with known illness or use of medications known to influence the neuromuscular transmission
  • Known significant renal or hepatic dysfunction
  • Allergy to medications used in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
AMGTOF-Watch SX (Acceleromyography)Acceleromygraphy monitoring
MMGTOF-Watch SX (Acceleromyography)Mechanomyography monitoring
Primary Outcome Measures
NameTimeMethod
Comparison of ED50 with the two methods
Secondary Outcome Measures
NameTimeMethod
Comparison of ED95 with the two methods

Trial Locations

Locations (1)

Rigshospitalet

🇩🇰

Copenhagen, Østerbro, Denmark

© Copyright 2025. All Rights Reserved by MedPath